Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SANTINI, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.537
EU - Europa 614
AS - Asia 460
SA - Sud America 61
AF - Africa 13
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.687
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.534
SG - Singapore 230
IT - Italia 224
CN - Cina 185
DE - Germania 110
GB - Regno Unito 58
BR - Brasile 47
IE - Irlanda 41
SE - Svezia 38
FI - Finlandia 35
RU - Federazione Russa 24
FR - Francia 15
UA - Ucraina 14
TR - Turchia 12
AT - Austria 10
NL - Olanda 10
RO - Romania 10
IR - Iran 9
BE - Belgio 7
CI - Costa d'Avorio 5
EC - Ecuador 5
IN - India 5
UZ - Uzbekistan 5
EG - Egitto 4
ES - Italia 4
JP - Giappone 4
CA - Canada 3
CL - Cile 3
LT - Lituania 3
MA - Marocco 3
AR - Argentina 2
BG - Bulgaria 2
LB - Libano 2
PL - Polonia 2
PY - Paraguay 2
VE - Venezuela 2
AL - Albania 1
DK - Danimarca 1
EU - Europa 1
GR - Grecia 1
HK - Hong Kong 1
HR - Croazia 1
ID - Indonesia 1
IL - Israele 1
IQ - Iraq 1
KR - Corea 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
OM - Oman 1
PT - Portogallo 1
TN - Tunisia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.687
Salva come PNG Salva come JPEG
Città #
Fairfield 750
Ashburn 354
Woodbridge 346
Seattle 286
Houston 285
Wilmington 249
Cambridge 225
Chandler 217
Singapore 134
Ann Arbor 116
Medford 67
Altamura 59
Lawrence 42
Princeton 42
Dublin 41
Des Moines 39
Dearborn 33
Nanjing 32
San Diego 30
London 29
Palermo 28
Ludwigshafen am Rhein 27
Helsinki 24
Santa Clara 24
Beijing 22
Berlin 18
Nanchang 15
Phoenix 15
Shenyang 15
Rome 14
Changsha 13
San Paolo di Civitate 13
Boardman 12
Jinan 12
Hebei 11
New York 11
Izmir 10
Nuremberg 10
Milan 9
Tianjin 9
Chicago 8
Tulsa 8
Brussels 7
Hangzhou 7
Redwood City 7
Tehran 7
Abidjan 5
Amsterdam 5
Falkenstein 5
Frankfurt am Main 5
Jiaxing 5
Lucera 5
Orange 5
Saint Petersburg 5
Turin 5
Cairo 4
Forest City 4
Guangzhou 4
Jacksonville 4
Kitzingen 4
Mehlingen 4
Messina 4
Moscow 4
Ningbo 4
Vienna 4
Zhengzhou 4
Bremen 3
Guayaquil 3
Los Angeles 3
Paris 3
Sandston 3
São Paulo 3
Betim 2
Campo Grande 2
Casteltermini 2
Chiswick 2
Columbus 2
Gallarate 2
Iesi 2
Kumar 2
Lanzhou 2
Munich 2
Porto Alegre 2
Prineville 2
Pune 2
Redmond 2
Rio de Janeiro 2
Samarate 2
Shanghai 2
Springfield 2
Taizhou 2
Tokyo 2
Toronto 2
Acton 1
Agadir 1
Alecrim 1
Andover 1
Antakya 1
Araras 1
Arcoverde 1
Totale 3.888
Salva come PNG Salva come JPEG
Nome #
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 190
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma 174
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 174
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases 173
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 162
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 158
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 157
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 156
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. 151
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 151
Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study 150
Cetuximab in small bowel adenocarcinoma: A new friend 147
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions 144
New molecular targets in bone metastases 142
A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) 138
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 128
Deregulation of dicer and mir-155 expression in liposarcoma 126
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting 122
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 121
Hepatocellular carcinoma treatment over sorafenib: Epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? 121
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 120
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 119
Use of the word “cured” for cancer patients—implications for patients and physicians: The Siracusa charter 116
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? 115
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 113
Update on capecitabine alone and in combination regimens in colorectal cancer patients 113
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 112
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 111
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 106
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 106
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 92
The use of same in chemotherapy-induced liver injury 80
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary 78
Recent advances in desmoid tumor therapy 74
Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment † 73
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 70
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 69
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas 53
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 49
S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens 47
Antitumor effect of cabozantinib in bone metastatic models of renal cell carcinoma 47
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 37
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 28
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 18
Small bowel carcinomas in celiac or Crohn's disease: Distinctive histophenotypic, molecular and histogenetic patterns 16
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 12
null 3
Totale 4.962
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.582
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020306 0 0 0 0 0 0 0 0 132 68 83 23
2020/2021670 49 30 65 69 44 27 52 57 53 99 68 57
2021/2022555 32 123 25 13 8 17 25 38 45 69 79 81
2022/2023691 64 173 14 51 62 96 29 64 77 6 37 18
2023/2024270 20 30 32 15 17 33 35 9 2 4 3 70
2024/2025494 14 85 46 47 23 56 63 103 57 0 0 0
Totale 4.962